Previous close | 302.77 |
Open | 309.13 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 300.77 - 309.13 |
52-week range | 298.00 - 430.00 |
Volume | |
Avg. volume | 6,596 |
Market cap | 252.413B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 15.61 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 10.47 (3.46%) |
Ex-dividend date | 16 Mar 2023 |
1y target est | N/A |
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery for people with early-stage hepatocellular carcinoma (HCC) at high risk of disease recurrence. The Tec
SOUTH SAN FRANCISCO, Calif., January 06, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. LBC
SOUTH SAN FRANCISCO, Calif., December 23, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Lunsumio® (mosunetuzumab-axgb) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingen